Payment overview · 2025
General Payments
$295.58
14 reported records · 8 companies
Healthcare provider profile · identity verified
Carla Odom
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · KOKOMO, MS · NPI 1043827900
Verified facts
What the public records show
CMS Open Payments records show Carla Odom received $295.58 in general payments during 2025 across 14 reported records.
Novo Nordisk Inc accounted for 27.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $81.48 | 27.6% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $67.33 | 22.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $56.04 | 19.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $38.91 | 13.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.10 | 5.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.94 | 5.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.86 | 5.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $2.92 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $295.58 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $67.33 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $65.20 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $56.04 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $38.91 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $38.91 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.16 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $2.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 274 | 83 |
| Gabapentin | Gabapentin | 203 | 61 |
| Azithromycin | Azithromycin | 156 | 128 |
| Atorvastatin Calcium | Atorvastatin Calcium | 155 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 143 | 49 |
| Tizanidine Hcl | Tizanidine Hcl | 124 | 51 |
| Meloxicam | Meloxicam | 120 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 119 | 34 |
| Metformin Hcl | Metformin Hcl | 119 | 39 |
| Lisinopril | Lisinopril | 114 | 34 |
| Potassium Chloride | Potassium Chloride | 108 | 33 |
| Furosemide | Furosemide | 107 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 103 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | 33 |
| Levothyroxine Sodium | Levothyroxine Sodium | 95 | 28 |
| Losartan Potassium | Losartan Potassium | 93 | 31 |
| Alprazolam | Alprazolam | 90 | 19 |
| Omeprazole | Omeprazole | 89 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 35 |
| Montelukast Sodium | Montelukast Sodium | 84 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 77 | 69 |
| Carvedilol | Carvedilol | 73 | 20 |
| Simvastatin | Simvastatin | 62 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 16 |
| Glimepiride | Glimepiride | 60 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 60 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 59 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 18 |
| Lorazepam | Lorazepam | 59 | 20 |
| Trazodone Hcl | Trazodone Hcl | 56 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 54 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 53 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 49 | 37 |
| Sertraline Hcl | Sertraline Hcl | 46 | 14 |
| Ibuprofen | Ibuprofen | 44 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 43 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 42 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 17 |
| Donepezil Hcl | Donepezil Hcl | 41 | suppressed |
| Fluconazole | Fluconazole | 38 | 26 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Prednisone | Prednisone | 37 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Allopurinol | Allopurinol | 34 | 16 |
| Tramadol Hcl | Tramadol Hcl | 34 | 19 |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 22 |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 25 |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 17 |
| Pregabalin | Pregabalin | 27 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 13 |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Famotidine | Famotidine | 22 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | 13 |
| Lovastatin | Lovastatin | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 21 |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 16 |
| Naproxen | Naproxen | 21 | 13 |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 11 |
| Finasteride | Finasteride | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 19 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 14 |
| Minoxidil | Minoxidil | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Eliquis | Apixaban | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $295.58 · 14 records | Novo Nordisk Inc | CAPLYTA, GVOKE HYPOPEN, JARDIANCE, MOUNJARO, OTEZLA, Ozempic, REPATHA, VOQUEZNA, Wegovy, XIFAXAN, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error